Micaela Morelli

List of Publications by Citations

160 papers	6,538 citations	42 h-index	76 g-index
162 ext. papers	7,108 ext. citations	5.1 avg, IF	5.59 L-index

#	Paper	IF	Citations
160	Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. *Trends in Neurosciences*, **1997**, 20, 482-7	13.3	676
159	Modulatory functions of neurotransmitters in the striatum: ACh/dopamine/NMDA interactions. *Trends in Neurosciences*, **1994**, 17, 228-33	13.3	417
158	Targeting adenosine A2A receptors in Parkinson's disease. *Trends in Neurosciences*, **2006**, 29, 647-54	13.3	364
157	Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease. *Progress in Neurobiology*, **2015**, 132, 96-168	10.9	282
156	The 6-hydroxydopamine model of Parkinson's disease. *Neurotoxicity Research*, **2007**, 11, 151-67	4.3	249
155	[3H]Ro5-4864 benzodiazepine binding in the kainate lesioned striatum and Huntington's diseased basal ganglia. *Brain Research*, **1982**, 248, 396-401	3.7	150
154	Amphetamine-related drugs neurotoxicity in humans and in experimental animals: Main mechanisms. *Progress in Neurobiology*, **2017**, 155, 149-170	10.9	135
153	Adenosine A2A receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats. *European Journal of Pharmacology*, **1997**, 321, 143-7	5.3	130
152	Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications. *Progress in Neurobiology*, **2007**, 83, 293-309	10.9	123
151	Catalepsy induced by SCH 23390 in rats. *European Journal of Pharmacology*, **1985**, 117, 179-85	5.3	119
150	MK-801 potentiates dopaminergic D1 but reduces D2 responses in the 6-hydroxydopamine model of Parkinson's disease. *European Journal of Pharmacology*, **1990**, 182, 611-2	5.3	93
149	Motor stimulant effects of the adenosine A(2A) receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats. *Synapse*, **2001**, 39, 233-238	2.4	92
148	Adenosine A2A receptors and Parkinson's disease. *Handbook of Experimental Pharmacology*, **2009**, 589-615	3.1	88
147	Adenosine A2 receptors interact negatively with dopamine D1 and D2 receptors in unilaterally 6-hydroxydopamine-lesioned rats. *European Journal of Pharmacology*, **1994**, 251, 21-5	5.3	85
146	Time and dose dependence of the 'priming' of the expression of dopamine receptor supersensitivity. *European Journal of Pharmacology*, **1989**, 162, 329-35	5.3	81
145	Pharmacological characterization of 50-kHz ultrasonic vocalizations in rats: comparison of the effects of different psychoactive drugs and relevance in drug-induced reward. *Neuropharmacology*, **2012**, 63, 224-34	5.5	80
144	Agonist-induced homologous and heterologous sensitization to D-1- and D-2-dependent contraversive turning. *European Journal of Pharmacology*, **1987**, 141, 101-7	5.3	78

143	New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists. *Life Sciences*, **2005**, 77, 3259-67	6.8	72
142	Anxiolytic-like effects of N,N-dialkyl-2-phenylindol-3-ylglyoxylamides by modulation of translocator protein promoting neurosteroid biosynthesis. *Journal of Medicinal Chemistry*, **2008**, 51, 5798-806	8.3	70
141	Adenosine A2A receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6-hydroxydopamine rat model of Parkinson's disease. *Synapse*, **2007**, 61, 606-14	2.4	68
140	Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats. *European Journal of Pharmacology*, **2007**, 566, 94-102	5.3	68
139	Blockade of adenosine A2A receptors antagonizes parkinsonian tremor in the rat tacrine model by an action on specific striatal regions. *Experimental Neurology*, **2004**, 189, 182-8	5.7	67
138	Pathophysiological roles for purines: adenosine, caffeine and urate. *Progress in Brain Research*, **2010**, 183, 183-208	2.9	65
137	Modification of adenosine extracellular levels and adenosine A(2A) receptor mRNA by dopamine denervation. *European Journal of Pharmacology*, **2002**, 446, 75-82	5.3	63
136	Benzodiazepine receptor binding in young, mature and senescent rat brain and kidney. *Neurobiology of Aging*, **1981**, 2, 83-8	5.6	60
135	Adenosine A2A receptor agonists increase Fos-like immunoreactivity in mesolimbic areas. *Brain Research*, **1997**, 759, 41-9	3.7	58
134	Assessment of symptomatic and neuroprotective efficacy of Mucuna pruriens seed extract in rodent model of Parkinson's disease. *Neurotoxicity Research*, **2009**, 15, 111-22	4.3	57
133	Inactivation of neuronal forebrain A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease. *Journal of Neurochemistry*, **2009**, 111, 1478-89	6	57
132	Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic-intermittent L-dopa and A2A receptor blockade plus L-dopa in dopamine-denervated rats. *Synapse*, **2002**, 44, 166-74	2.4	57
131	Late-onset Parkinsonism in NFB/c-Rel-deficient mice. *Brain*, **2012**, 135, 2750-65	11.2	55
130	Synthesis of ibuprofen heterocyclic amides and investigation of their analgesic and toxicological properties. *European Journal of Medicinal Chemistry*, **2003**, 38, 513-8	6.8	53
129	Expression of c-fos protein in the experimental epilepsy induced by pilocarpine. *Synapse*, **1993**, 14, 1-9	2.4	52
128	Involvement of adenosine A2A receptors in the induction of c-fos expression by clozapine and haloperidol. *Neuropsychopharmacology*, **1999**, 20, 44-51	8.7	51
127	Direct and long-lasting effects elicited by repeated drug administration on 50-kHz ultrasonic vocalizations are regulated differently: implications for the study of the affective properties of drugs of abuse. *International Journal of Neuropsychopharmacology*, **2014**, 17, 429-41	5.8	49
126	L-dopa stimulates c-fos expression in dopamine denervated striatum by combined activation of D-1 and D-2 receptors. *Brain Research*, **1993**, 623, 334-6	3.7	49

125	Impulse control disorders and dopamine dysregulation syndrome associated with dopamine agonist therapy in Parkinson's disease. *Behavioural Pharmacology*, **2009**, 20, 363-79	2.4	48
124	Substantia nigra as a site of origin of dopamine-dependent motor syndromes induced by stimulation of mu and delta opioid receptors. *Brain Research*, **1989**, 487, 120-30	3.7	46
123	Dyskinesia in Parkinson's disease: mechanisms and current non-pharmacological interventions. *Journal of Neurochemistry*, **2014**, 130, 472-89	6	44
122	Lesions of substantia nigra by kainic acid: effects on apomorphine-induced stereotyped behaviour. *Brain Research*, **1980**, 191, 67-78	3.7	44
121	Subchronic caffeine exposure induces sensitization to caffeine and cross-sensitization to amphetamine ipsilateral turning behavior independent from dopamine release. *Neuropsychopharmacology*, **2003**, 28, 1752-9	8.7	42
120	Role of neuroactive steroid allopregnanolone in antipsychotic-like action of olanzapine in rodents. *Neuropsychopharmacology*, **2004**, 29, 1597-609	8.7	42
119	Adenosine A2A receptor antagonism increases striatal glutamate outflow in dopamine-denervated rats. *European Journal of Pharmacology*, **2003**, 464, 33-8	5.3	42
118	Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson's disease. *Molecular Neurodegeneration*, **2016**, 11, 6	19	41
117	Perinatal asphyxia: current status and approaches towards neuroprotective strategies, with focus on sentinel proteins. *Neurotoxicity Research*, **2011**, 19, 603-27	4.3	41
116	Caffeine enhances astroglia and microglia reactivity induced by 3,4-methylenedioxymethamphetamine ('ecstasy') in mouse brain. *Neurotoxicity Research*, **2010**, 17, 435-9	4.3	41
115	Acute perinatal asphyxia impairs non-spatial memory and alters motor coordination in adult male rats. *Experimental Brain Research*, **2008**, 185, 595-601	2.3	40
114	MPTP-induced dopamine neuron degeneration and glia activation is potentiated in MDMA-pretreated mice. *Movement Disorders*, **2013**, 28, 1957-65	7	39
113	Birth asphyxia as the major complication in newborns: moving towards improved individual outcomes by prediction, targeted prevention and tailored medical care. *EPMA Journal*, **2011**, 2, 197-210	8.8	39
112	Behavioural expression of D-1 receptor supersensitivity depends on previous stimulation of D-2 receptors. *Life Sciences*, **1987**, 40, 245-51	6.8	39
111	A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug. *Neuropharmacology*, **2010**, 58, 613-23	5.5	38
110	Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat. *Synapse*, **2008**, 62, 524-33	2.4	38
109	Induction of Fos-like-immunoreactivity in the central extended amygdala by antidepressant drugs. *Synapse*, **1999**, 31, 1-4	2.4	38
108	Nicotinamide prevents the long-term effects of perinatal asphyxia on apoptosis, non-spatial working memory and anxiety in rats. *Experimental Brain Research*, **2010**, 202, 1-14	2.3	37

107	New adenosine A2A receptor antagonists: actions on Parkinson's disease models. *European Journal of Pharmacology*, **2005**, 512, 157-64	5.3	37
106	Chapter I The organization and circuits of mesencephalic dopaminergic neurons and the distribution of dopamine receptors in the brain. *Handbook of Chemical Neuroanatomy*, **2005**, 1-107		36
105	Expression of dyskinetic movements and turning behaviour in subchronic L-DOPA 6-hydroxydopamine-treated rats is influenced by the testing environment. *Behavioural Brain Research*, **2006**, 171, 175-8	3.4	36
104	MDMA administration during adolescence exacerbates MPTP-induced cognitive impairment and neuroinflammation in the hippocampus and prefrontal cortex. *Psychopharmacology*, **2014**, 231, 4007-18	4.7	35
103	Microglial and astroglial activation by 3,4-methylenedioxymethamphetamine (MDMA) in mice depends on S(+) enantiomer and is associated with an increase in body temperature and motility. *Journal of Neurochemistry*, **2013**, 124, 69-78	6	35
102	[3H]CL 218,872, a novel triazolopyridazine which labels the benzodiazepine receptors in rat brain. *European Journal of Pharmacology*, **1982**, 77, 351-4	5.3	35
101	Repeated amphetamine administration and long-term effects on 50-kHz ultrasonic vocalizations: possible relevance to the motivational and dopamine-stimulating properties of the drug. *European Neuropsychopharmacology*, **2015**, 25, 343-55	1.2	34
100	Anxiolytic properties of a 2-phenylindolglyoxylamide TSPO ligand: Stimulation of in vitro neurosteroid production affecting GABAA receptor activity. *Psychoneuroendocrinology*, **2011**, 36, 463-72	5	34
99	Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease. *Movement Disorders*, **2016**, 31, 501-11	7	30
98	Behavioural sensitization in 6-hydroxydopamine-lesioned rats is related to compositional changes of the AP-1 transcription factor: evidence for induction of FosB- and JunD-related proteins. *Molecular Brain Research*, **1997**, 52, 307-17		29
97	Sensitization to caffeine and cross-sensitization to amphetamine: influence of individual response to caffeine. *Behavioural Brain Research*, **2006**, 172, 72-9	3.4	29
96	Local cerebral glucose utilization after D1 receptor stimulation in 6-OHDA lesioned rats: effect of sensitization (priming) with a dopaminergic agonist. *Synapse*, **1993**, 13, 264-9	2.4	29
95	Involvement of Glutamate NMDA Receptors in the Acute, Long-Term, and Conditioned Effects of Amphetamine on Rat 50 kHz Ultrasonic Vocalizations. *International Journal of Neuropsychopharmacology*, **2015**, 18, pyv057	5.8	28
94	Differential effect of MK 801 and scopolamine on c-fos expression induced by L-dopa in the striatum of 6-hydroxydopamine lesioned rats. *Synapse*, **1994**, 18, 288-93	2.4	27
93	Synthesis of new 2-arylamino-6-trifluoromethylpyridine-3-carboxylic acid derivatives and investigation of their analgesic activity. *Bioorganic and Medicinal Chemistry*, **2004**, 12, 4169-77	3.4	25
92	Dopamine and adenosine receptor interaction as basis for the treatment of Parkinson's disease. *Journal of the Neurological Sciences*, **2006**, 248, 48-52	3.2	24
91	Subchronic caffeine administration sensitizes rats to the motor-activating effects of dopamine D(1) and D(2) receptor agonists. *Psychopharmacology*, **2002**, 162, 246-54	4.7	24
90	Role of adenosine A receptors in motor control: relevance to Parkinson's disease and dyskinesia. *Journal of Neural Transmission*, **2018**, 125, 1273-1286	4.3	23

89	Biomarkers for prediction and targeted prevention of Alzheimer's and Parkinson's diseases: evaluation of drug clinical efficacy. *EPMA Journal*, **2010**, 1, 273-92	8.8	23
88	Cross-sensitization between the motor activating effects of bromocriptine and caffeine: role of adenosine A(2A) receptors. *Behavioural Brain Research*, **2000**, 114, 97-105	3.4	23
87	Changes in the D1 receptor-adenylate cyclase complex after priming. *European Journal of Pharmacology*, **1990**, 180, 365-7	5.3	23
86	Activation of adenosine A2A receptors suppresses the emission of pro-social and drug-stimulated 50-kHz ultrasonic vocalizations in rats: possible relevance to reward and motivation. *Psychopharmacology*, **2016**, 233, 507-19	4.7	22
85	Increase of dopamine D2(High) receptors in the striatum of rats sensitized to caffeine motor effects. *Synapse*, **2008**, 62, 394-7	2.4	22
84	How reliable is the behavioural evaluation of dyskinesia in animal models of Parkinson's disease?. *Behavioural Pharmacology*, **2006**, 17, 393-402	2.4	22
83	Blockade of A2A receptors plus l-DOPA after nigrostriatal lesion results in GAD67 mRNA changes different from l-DOPA alone in the rat globus pallidus and substantia nigra reticulata. *Experimental Neurology*, **2003**, 184, 679-87	5.7	22
82	6-Hydroxydopamine lesions reduce specific [3H]sulpiride binding in the rat substantia nigra: direct evidence for the existence of nigral D-2 autoreceptors. *European Journal of Pharmacology*, **1987**, 140, 99-104	5.3	22
81	A critical evaluation of behavioral rodent models of motor impairment used for screening of antiparkinsonian activity: The case of adenosine A(2A) receptor antagonists. *Neurotoxicity Research*, **2014**, 25, 392-401	4.3	21
80	Priming of 6-hydroxydopamine-lesioned rats with L-DOPA or quinpirole results in an increase in dopamine D1 receptor-dependent cyclic AMP production in striatal tissue. *European Journal of Pharmacology*, **1997**, 331, 23-6	5.3	21
79	Potentiation of amphetamine-mediated responses in caffeine-sensitized rats involves modifications in A2A receptors and zif-268 mRNAs in striatal neurons. *Journal of Neurochemistry*, **2006**, 98, 1078-89	6	21
78	EEG modifications in the cortex and striatum after dopaminergic priming in the 6-hydroxydopamine rat model of Parkinson's disease. *Brain Research*, **2003**, 972, 177-85	3.7	21
77	The effect of temperature on CL 218872 and propyl beta-carboline-3-carboxylate inhibition of [3H]-flunitrazepam binding in rat brain. *Biochemical and Biophysical Research Communications*, **1982**, 105, 1532-7	3.4	21
76	Influence of caffeine on 3,4-methylenedioxymethamphetamine-induced dopaminergic neuron degeneration and neuroinflammation is age-dependent. *Journal of Neurochemistry*, **2016**, 136, 148-62	6	21
75	Neuroprotective and anti-inflammatory effects of the adenosine A(2A) receptor antagonist ST1535 in a MPTP mouse model of Parkinson's disease. *Synapse*, **2011**, 65, 181-8	2.4	20
74	Neuropharmacology of the adenosine A2A receptors. *Drug Development Research*, **1996**, 39, 450-460	5.1	20
73	Progression and Persistence of Neurotoxicity Induced by MDMA in Dopaminergic Regions of the Mouse Brain and Association with Noradrenergic, GABAergic, and Serotonergic Damage. *Neurotoxicity Research*, **2017**, 32, 563-574	4.3	19
72	Metformin Prevented Dopaminergic Neurotoxicity Induced by 3,4-Methylenedioxymethamphetamine Administration. *Neurotoxicity Research*, **2016**, 30, 101-9	4.3	19

71	Biomarkers for evaluation of clinical efficacy of multipotential neuroprotective drugs for Alzheimer's and Parkinson's diseases. *Neurotherapeutics*, **2009**, 6, 128-40	6.4	19
70	Priming as a Model of Behavioural Sensitization. *Developmental Pharmacology and Therapeutics*, **1992**, 18, 223-227		19
69	NCX1 and NCX3 as potential factors contributing to neurodegeneration and neuroinflammation in the A53T transgenic mouse model of Parkinson's Disease. *Cell Death and Disease*, **2018**, 9, 725	9.8	19
68	Methylxanthines and drug dependence: a focus on interactions with substances of abuse. *Handbook of Experimental Pharmacology*, **2011**, 483-507	3.2	18
67	Odor Identification Performance in Idiopathic Parkinson's Disease Is Associated With Gender and the Genetic Variability of the Olfactory Binding Protein. *Chemical Senses*, **2019**, 44, 311-318	4.8	17
66	Involvement of globus pallidus in the antiparkinsonian effects of adenosine A(2A) receptor antagonists. *Experimental Neurology*, **2006**, 202, 255-7	5.7	17
65	Adenosine A2A and dopamine receptor interactions in basal ganglia of dopamine denervated rats. *Neurology*, **2003**, 61, S39-43	6.5	17
64	Modulation of Rat 50-kHz Ultrasonic Vocalizations by Glucocorticoid Signaling: Possible Relevance to Reward and Motivation. *International Journal of Neuropsychopharmacology*, **2018**, 21, 73-83	5.8	17
63	Performance of movement in hemiparkinsonian rats influences the modifications induced by dopamine agonists in striatal efferent dynorphinergic neurons. *Experimental Neurology*, **2013**, 247, 663-72	5.7	16
62	Adenosine A2A antagonists: potential preventive and palliative treatment for Parkinson's disease. *Experimental Neurology*, **2003**, 184, 20-3	5.7	16
61	Differential induction of Fos-like-immunoreactivity in the extended amygdala after haloperidol and clozapine. *Neuropsychopharmacology*, **1999**, 21, 93-100	8.7	16
60	Dyskinetic potential of dopamine agonists is associated with different striatonigral/striatopallidal zif-268 expression. *Experimental Neurology*, **2010**, 224, 395-402	5.7	15
59	Rehabilitation improves dyskinesias in Parkinsonian patients: a pilot study comparing two different rehabilitative treatments. *NeuroRehabilitation*, **2012**, 30, 295-301	2	15
58	Direct and indirect striatal efferent pathways are differentially influenced by low and high dyskinetic drugs: behavioural and biochemical evidence. *Parkinsonism and Related Disorders*, **2008**, 14 Suppl 2, S165-8	3.6	15
57	Neurochemical and Neurotoxic Effects of MDMA (Ecstasy) and Caffeine After Chronic Combined Administration in Mice. *Neurotoxicity Research*, **2018**, 33, 532-548	4.3	15
56	A preclinical study on the combined effects of repeated eltoprazine and preladenant treatment for alleviating L-DOPA-induced dyskinesia in Parkinson's disease. *European Journal of Pharmacology*, **2017**, 813, 10-16	5.3	14
55	The effect of GABA on in vitro binding of two novel non-benzodiazepines, PK 8165 and CGS 8216, to benzodiazepine receptors in the rat brain. *Life Sciences*, **1982**, 31, 77-81	6.8	14
54	Lack of Rhes Increases MDMA-Induced Neuroinflammation and Dopamine Neuron Degeneration: Role of Gender and Age. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	13

53	6-n-propylthiouracil taste disruption and TAS2R38 nontasting form in Parkinson's disease. *Movement Disorders*, **2018**, 33, 1331-1339	7	13
52	Effect of crowding, temperature and age on glia activation and dopaminergic neurotoxicity induced by MDMA in the mouse brain. *NeuroToxicology*, **2016**, 56, 127-138	4.4	13
51	A(2A) Receptor Antagonism and Dyskinesia in Parkinson's Disease. *Parkinson's Disease*, **2012**, 2012, 489854	2.6	13
50	Behavioral, neurochemical, and electrophysiological changes in an early spontaneous mouse model of nigrostriatal degeneration. *Neurotoxicity Research*, **2011**, 20, 170-81	4.3	12
49	Priming of rotational behavior by a dopamine receptor agonist in Hemiparkinsonian rats: movement-dependent induction. *Neuroscience*, **2009**, 158, 1625-31	3.9	12
48	Loss of striatal neurons after local microinjection of colchicine. *Neuroscience Letters*, **1980**, 16, 131-5	3.3	12
47	Decreased Rhes mRNA levels in the brain of patients with Parkinson's disease and MPTP-treated macaques. *PLoS ONE*, **2017**, 12, e0181677	3.7	12
46	Genetic variants of TAS2R38 bitter taste receptor associate with distinct gut microbiota traits in Parkinson's disease: A pilot study. *International Journal of Biological Macromolecules*, **2020**, 165, 665-674	7.9	12
45	The Small GTP-Binding Protein Rhes Influences Nigrostriatal-Dependent Motor Behavior During Aging. *Movement Disorders*, **2016**, 31, 583-9	7	10
44	Blockade of globus pallidus adenosine A(2A) receptors displays antiparkinsonian activity in 6-hydroxydopamine-lesioned rats treated with D(1) or D(2) dopamine receptor agonists. *Synapse*, **2008**, 62, 345-51	2.4	10
43	Metabolic mapping of the synergism between MK-801 and SKF 38393 in rats with unilateral lesions of the dopaminergic nigrostriatal pathway. *Synapse*, **1992**, 12, 255-60	2.4	10
42	Clinical Phenotypes of Parkinson's Disease Associate with Distinct Gut Microbiota and Metabolome Enterotypes. *Biomolecules*, **2021**, 11,	5.9	10
41	Repeated Administration of 3,4-Methylenedioxymethamphetamine (MDMA) Elevates the Levels of Neuronal Nitric Oxide Synthase in the Nigrostriatal System: Possible Relevance to Neurotoxicity. *Neurotoxicity Research*, **2018**, 34, 763-768	4.3	9
40	Elevation of striatal urate in experimental models of Parkinson's disease: a compensatory mechanism triggered by dopaminergic nigrostriatal degeneration?. *Journal of Neurochemistry*, **2014**, 131, 284-9	6	9
39	Intensive rehabilitation treatment in parkinsonian patients with dyskinesias: a preliminary study with 6-month followup. *Parkinson's Disease*, **2012**, 2012, 910454	2.6	9
38	Gender Differences in Neurodegeneration, Neuroinflammation and Na-Ca Exchangers in the Female A53T Transgenic Mouse Model of Parkinson's Disease. *Frontiers in Aging Neuroscience*, **2020**, 12, 118	5.3	6
37	Rhes Counteracts Dopamine Neuron Degeneration and Neuroinflammation Depending on Gender and Age. *Frontiers in Aging Neuroscience*, **2018**, 10, 163	5.3	6
36	Contribution of Caffeine to the Psychostimulant, Neuroinflammatory and Neurotoxic Effects of Amphetamine-Related Drugs. *Journal of Caffeine Research*, **2013**, 3, 79-84		6

35	Alteration in the progression of dopamine neuron degeneration: may caffeine offer new perspective?. *Experimental Neurology*, **2012**, 237, 218-22	5.7	6
34	Subchronic intermittent caffeine administration to unilaterally 6-hydroxydopamine-lesioned rats sensitizes turning behaviour in response to dopamine D(1) but not D(2) receptor agonists. *Behavioural Pharmacology*, **2005**, 16, 621-6	2.4	6
33	Influence of dopamine transmission in the medial prefrontal cortex and dorsal striatum on the emission of 50-kHz ultrasonic vocalizations in rats treated with amphetamine: Effects on drug-stimulated and conditioned calls. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2020**, 97, 109797	5.5	6
32	Gut microbiota and metabolome distinctive features in Parkinson disease: Focus on levodopa and levodopa-carbidopa intrajejunal gel. *European Journal of Neurology*, **2021**, 28, 1198-1209	6	6
31	Output Pathways Mediating Basal Ganglia Function. *Advances in Behavioral Biology*, **1984**, 443-466		6
30	C-Fos expression as a molecular marker in corticotropin-releasing factor-induced seizures. *Synapse*, **1996**, 24, 297-304	2.4	5
29	Role of movement in long-term basal ganglia changes: implications for abnormal motor responses. *Frontiers in Computational Neuroscience*, **2013**, 7, 142	3.5	4
28	Role of dopamine receptors in the induction and expression of rotational behavior induced by caffeine in 6-hydroxydopamine-lesioned rats. *Drug Development Research*, **1998**, 45, 373-378	5.1	4
27	What Do You See as the Main Priorities, Opportunities, and Challenges in Caffeine Research in the Next Five Years?. *Journal of Caffeine Research*, **2011**, 1, 5-12		3
26	Involvement of the Protein Ras Homolog Enriched in the Striatum, Rhes, in Dopaminergic Neurons' Degeneration: Link to Parkinson's Disease. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	3
25	Increased emissions of 50-kHz ultrasonic vocalizations in hemiparkinsonian rats repeatedly treated with dopaminomimetic drugs: A potential preclinical model for studying the affective properties of dopamine replacement therapy in Parkinson's disease. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2021**, 108, 110184	5.5	3
24	Acetylcholine, Dopamine and NMDA Transmission in the Caudate-Putamen: Their Interaction and Function as a Striatal Modulatory System. *Advances in Behavioral Biology*, **1994**, 491-505		3
23	Symptomatic and Neuroprotective Effects of A2A Receptor Antagonists in Parkinson Disease **2013**, 361-384		3
22	Pharmacological interactions between adenosine A receptor antagonists and different neurotransmitter systems. *Parkinsonism and Related Disorders*, **2020**, 80 Suppl 1, S37-S44	3.6	2
21	Antagonism of Adenosine A1 or A2A Receptors Amplifies the Effects of MDMA on Glial Activation in the Mouse Brain: Relevance to Caffeine MDMA Interactions. *Journal of Caffeine Research*, **2014**, 4, 41-47		2
20	Can dietary substances protect against Parkinson's disease? The case of caffeine. *Experimental Neurology*, **2010**, 225, 246-9	5.7	2
19	Modulation by adenosine A2A receptors of dopamine-mediated motor behavior as a basis for antiparkinson disease drugs. *Drug Development Research*, **2001**, 52, 387-393	5.1	2
18	In utero exposure to dexamethasone causes a persistent and age-dependent exacerbation of the neurotoxic effects and glia activation induced by MDMA in dopaminergic brain regions of C57BL/6J mice. *NeuroToxicology*, **2021**, 83, 1-13	4.4	2

17	Brief history of the medical and non-medical use of amphetamine-like psychostimulants. *Experimental Neurology*, **2021**, 342, 113754	5.7	2
16	Neuroinflammation and L-dopa-induced abnormal involuntary movements in 6-hydroxydopamine-lesioned rat model of Parkinson's disease are counteracted by combined administration of a 5-HT receptor agonist and A receptor antagonist. *Neuropharmacology*, **2021**, 196, 108693	5.5	2
15	Irreversible neuronal damage after intrastriatal injection of colchicine. *Pharmacological Research Communications*, **1980**, 12, 719-23		1
14	Adenosine A2A Receptor Antagonists in L-DOPA-Induced Motor Fluctuations. *Current Topics in Neurotoxicity*, **2015**, 163-182		1
13	Methylxanthines and Drug Dependence: Interactions and Toxicity **2016**, 912-923		1
12	Activation of Antioxidant and Proteolytic Pathways in the Nigrostriatal Dopaminergic System After 3,4-Methylenedioxymethamphetamine Administration: Sex-Related Differences. *Frontiers in Pharmacology*, **2021**, 12, 713486	5.6	1
11	Fos expression induced by olanzapine and risperidone in the central extended amygdala. *European Journal of Pharmacology*, **2019**, 865, 172764	5.3	0
10	Protective Agents in Parkinson's Disease: Caffeine and Adenosine A2A Receptor Antagonists **2014**, 2281-2298		0
9	Control of Motor Function by Adenosine A 2A Receptors in Parkinson's and Huntington's Disease **2017**, 187-213		
8	Role of Adenosine in the Basal Ganglia. *Handbook of Behavioral Neuroscience*, **2010**, 201-217	0.7	
7	Priming of the expression of dopamine D-1 receptor supersensitivity: Beavioural and neurochemical studies. *Pharmacological Research Communications*, **1988**, 20, 255		
6	Changes in the Expression of Tonic and Phasic Neurochemical Markers of Activity in a Rat Model of L-DOPA Induced Dyskinesia **2005**, 371-378		
5	Protective Agents in Parkinson's Disease: Caffeine and Adenosine A2A Receptor Antagonists **2021**, 1-24		
4	Different Patterns of Behavior and Gene Expression Induced by Chronic L-Dopa and A2A Antagonists Plus L-Dopa Treatments in 6- Hydroxydopamine Lesioned Rats. *Advances in Behavioral Biology*, **2002**, 19-28		
3	The Influence of Priming on the Behavioral Expression of Dopamine Receptor Supersensitivity in Basal Ganglia. *Advances in Behavioral Biology*, **1990**, 579-584		
2	Priming of the Behavioral Expression of Dopamine-Receptor Supersensitivity in the Basal Ganglia: Pharmacological and Biochemical Studies. *Advances in Behavioral Biology*, **1991**, 443-452		
1	Behavioural Correlates of Dopaminergic Agonists' Dyskinetic Potential in the 6-OHDA-Lesioned Rat. *Advances in Behavioral Biology*, **2009**, 461-470		